Latest stories on HCM
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
StockTitan56 · neutralproduct/pr
Hutchmed announces SANOVO trial meets primary endpoint
The Fly74 · bullishproduct/pr
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026
Business Insider74 · bullishproduct/pr
HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine
Business Insider74 · bullishproduct/pr
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
Business Insider64 · neutralproduct/pr
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
GlobeNewswire64 · neutralproduct/pr
Hutchmed Advances HMPL-A830 Trial, Keeping Oncology Pipeline – And Investor Interest – Alive
TipRanks63 · neutralproduct/pr
Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC
The Fly63 · neutralproduct/pr
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
GlobeNewswire63 · neutralproduct/pr
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
Business Insider63 · neutralproduct/pr
Why is HUTCHMED China stock gaining today?
Investing.com Markets50 · neutralgeneral
Hutchmed initiates Phase Ia part of trial of HMPL-A830
The Fly56 · neutralproduct/pr
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
Business Insider63 · neutralproduct/pr
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
Business Insider56 · neutralproduct/pr
Hutchmed price target raised to $18 from $16 at BofA
The Fly61 · neutralanalyst
Hannah Cranston Media (HCM) Named to The PR Net 100 2026, Cementing Its Place Among the Most Powerful PR Agencies Globally
PR Newswire73 · bullishproduct/pr
Hutchmed upgraded to Buy from Hold at HSBC
The Fly61 · neutralanalyst
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 - Slideshow
Seeking Alpha56 · neutralproduct/pr
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
Yahoo Top73 · bullishm&a
Hutchmed extends rally to 17% after Daiwa upgrades to Buy
The Fly68 · bullishanalyst
Hutchmed upgraded to Buy from Hold at Daiwa
The Fly61 · neutralanalyst
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript
Seeking Alpha63 · neutralproduct/pr
Why is HUTCHMED stock surging today?
Investing.com Markets50 · neutralgeneral